Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

KalVista Pharmaceuticals (KALV) Share-based Compensation (2016 - 2025)

Historic Share-based Compensation for KalVista Pharmaceuticals (KALV) over the last 10 years, with Q2 2025 value amounting to $3.6 million.

  • KalVista Pharmaceuticals' Share-based Compensation fell 7141.96% to $3.6 million in Q2 2025 from the same period last year, while for Apr 2025 it was $22.4 million, marking a year-over-year increase of 232.26%. This contributed to the annual value of $12.3 million for FY2025, which is 4391.51% down from last year.
  • Per KalVista Pharmaceuticals' latest filing, its Share-based Compensation stood at $3.6 million for Q2 2025, which was down 7141.96% from $3.0 million recorded in Q4 2024.
  • In the past 5 years, KalVista Pharmaceuticals' Share-based Compensation ranged from a high of $12.7 million in Q2 2024 and a low of $2.7 million during Q1 2024
  • Its 3-year average for Share-based Compensation is $4.5 million, with a median of $3.2 million in 2023.
  • Per our database at Business Quant, KalVista Pharmaceuticals' Share-based Compensation crashed by 648.58% in 2024 and then tumbled by 7141.96% in 2025.
  • KalVista Pharmaceuticals' Share-based Compensation (Quarter) stood at $3.2 million in 2023, then decreased by 6.49% to $3.0 million in 2024, then rose by 21.44% to $3.6 million in 2025.
  • Its Share-based Compensation stands at $3.6 million for Q2 2025, versus $3.0 million for Q4 2024 and $3.0 million for Q3 2024.